{"paper_id":"cafda02e-8ccb-49c7-8547-90e88cccb989","body_text":"Abstract\nAim\nThe aim of this study was to compare the efficiency of dopamine agonist, Cabergoline, in decreasing the size of endometrioma, with that of luteinizing hormone releasing hormone (LHRH) agonist, triptorelin acetate.\nStudy\nThis was a prospective, randomized study.\nSetting\nThe setting was in two private medical centers in the UAE, from January 2011 to February 2012.\nPatients and methods\nOne hundred and forty patients complaining of endometrioma, and fulfilling the eligibility criteria, were chosen and divided into two groups as follows: Group I comprised 71 patients; all of them received Cabergoline tablets, 0.5 mg tablets, twice per week for 12 weeks. Group II comprised 69 patients; all of them received LHRH agonist, decapeptyl, 3.75 mg subcutaneous, single injection, once a month for 3 months. All patients underwent vaginal ultrasound before and after the treatment period to compare the change in the size of endometrioma by the same sonography team in each hospital that was blind to the treatment groups.\nOutcome\nThe outcome was measured by the changes in the endometrioma size by vaginal ultrasound after completion of the 3 months’ treatment period. The management line was considered to be significantly effective if the endometrioma size was reduced by more than 25 % of its original pretreatment size.\nResults\nGroup I: 46 out of the 71 patients (64.7 %) had significant decrease in endometrioma size. Group II: 15 out of 69 patients (21.7 %) had significant decrease in endometrioma size. Paired t test to compare the means of the two groups was highly significant (p < 0.05)\nConclusion\nCabergoline (dostinex) yields better results in decreasing the size of endometrioma, compared to LHRH-agonist by exerting antiangiogenic effects through vascular endothelial growth factor receptor-2 (VEGFR-2) inactivation. It has no major side effects, easier to administer, and cheaper than LHRH agonists.\nSimilar content being viewed by others\nChange history\n05 March 2026\nAn Editorial Expression of Concern to this paper has been published: https://doi.org/10.1007/s00404-026-08374-7\nReferences\nMalinak LR, Buttram VC Jr, Elias S, Simpson JL (1980) Heritage aspects of endometriosis. Clinical characteristics of endometriosis. Am J Obstet Gynecol 137:332–337\nMay K, Becker CM (2008) Endometriosis and angiogenesis. Minerva Ginecol 60(3):245–254\nBrosens IA, Puttemans PJ, Deprest J (1994) The endoscopic localization of endometrial implants in the ovarian chocolate cyst. Fertil Steril 61(6):1034\nRyan IP, Taylor RN (1997) Endometriosis and infertility: new concepts. Obstet Gynecol Surv 52:365–371\nNisolle M, Casanas- Roux, Anaf V, Mine J, Donnez J (1993) Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril 59:681–684\nNovella-Maestre E, Carda C, Ruiz-Sauri A, Garcia-Velasco JA, Simon C, Pellicer A (2010) Identification and quantification of dopamine receptor 2 in human eutopic and ectopic endometrium: a novel molecular target for endometriosis therapy. Biol Reprod 83(5):866–873\nTaylor RN, Ryan IP, Moore E, Hornung D, Shiffren J, Tseng J (1997) Angiogenesis and macrophage activation in endometriosis. Ann NY Acad Sci 828:194–207\nBecker CM, D’Amato RJ (2007) Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc Res 74:121–130\nDvorak HF (2006) Discovery of vascular permeability factor (VPF). Exp Cell Res 312:522–526\nDonnez J, Smoes P, Gillerot S, Casana-Roux F, Nisolle M (1996) Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 13:1686–1690\nFasciani A, D’Ambrogio G, Bocci G, Monti M, Genazzani AR, Artini PG (2006) High concentrations of the vascular endothelial growth factor (VEGF) and interleukin-8 in ovarian endometriomata. Mol Hum Reprod 6:50–54\nNisolle M, Alvarez ML, Colombo M, Foidart JM (2007) Pathogenesis of endometriosis. Gynecol Obstet Fertil 35(9):898–903\nMcLaren J, Prentice A, Charnock-Jones DS et al (1996) Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 98:482–489\nMueller MD, Lebovic DI, Garrett E, Taylor RN (2000) Neutrophils infiltrating the endometrium express vascular endothelial growth factor (VEGF): potential role in endometrial angiogenesis. Fertil Steril 74:107–112\nHanahan D, Folkman J (1996) Patterns of emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364\nFedele L, Bianchi S, Di Nola G, Candiani M, Busacca M, Vignali M (1994) The recurrence of endometriosis. Ann NY Acad Sci 734:358–364\nGuo SW (2009) Recurrence of endometriosis and its control. Hum Reprod Update 15:441–461\nWaller KG, Shaw RW (1993) Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 59(3):511–515\nGroothuis PG, Nap AW, Winterhager E, Grümmer R (2005) Vascular development in endometriosis. Angiogenesis 8:147–156\nBecker CM, D’Amato RJ (2007) Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc Res 74:121–130\nMay K, Becker C (2008) Endometriosis and angiogenesis. Minerva Ginecol 60:245–254\nTaylor RN, Yu J, Torres PB, Schickedanz AC, Park JK, Mueller MD, Sidell N (2009) Mechanistic and therapeutic implications of angiogenesis in endometriosis. Reprod Sci 16:140–146\nTaylor RN, Lebovic DI, Mueller MD (2002) Angiogenic factors in endometriosis. Ann NY Acad Sci 955:89–100\nLazarus A, Keshet E (2011) Vascular endothelial growth factor and vascular homeostasis. Proc Am Thorac Soc 8:508–511\nLeung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309\nBasu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, anseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D (2001) The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569–574\nTaylor RN, Jie Yu, Torres Paulo B, Schickendanz Aimee C, park John K, Mueller Michael D, Sidell Neil (2009) Mechanistic and therapeutic implications of angiogenesis in endometriosis. Reprod Sci 16(2):140–146\nMelli MS, Farzadi L, Madarek EO (2007) Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression. Saudi Med J 28(3):445–450\nNovella-Maestre E, Carda C, Noguera I, Ruiz-Saurí A, García-Velasco JA, Simón C, Pellicer A (2009) Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod 24(5):1025–1035\nDelgado-Rosas F, Gómez R, Ferrero H, Gaytan F, Garcia-Velasco J, Simón C, Pellicer A (2011) The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis. Reproduction 142(5):745–755\nScarpellini F, Sbracia M, Lecchini S, Scarpellini L (2002) Antiangiogenesis treatment with thalidomide in endometriosis: a pilot study. Fertil Steril 78:S87\nBatioglu S, celikkanat H, Ugur M, Mollamhmutoglu L, Yesilyurt H, Kundakci M (1996) The use of GnRH agonists in the treatment of endometriomas, with or without drainage. J Pak Med associ 46:30–32\nConflict of interest\nNone.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nHamid, A.M.S.A., Madkour, W.A.I., Moawad, A. et al. Does Cabergoline help in decreasing endometrioma size compared to LHRH agonist? A prospective randomized study. Arch Gynecol Obstet 290, 677–682 (2014). https://doi.org/10.1007/s00404-014-3242-4\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-014-3242-4","source_license":"CC0","license_restricted":false}